Cargando…
Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?
SIMPLE SUMMARY: Epigenetic events, which comprise post-translational modifications of histone tails or DNA methylation, control gene expression by altering chromatin structure without change in the DNA sequence. Histone tails modifications are driven by specific cellular enzymes such as histone meth...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563040/ https://www.ncbi.nlm.nih.gov/pubmed/36230787 http://dx.doi.org/10.3390/cancers14194865 |
_version_ | 1784808312761483264 |
---|---|
author | Krossa, Imène Strub, Thomas Aplin, Andrew E. Ballotti, Robert Bertolotto, Corine |
author_facet | Krossa, Imène Strub, Thomas Aplin, Andrew E. Ballotti, Robert Bertolotto, Corine |
author_sort | Krossa, Imène |
collection | PubMed |
description | SIMPLE SUMMARY: Epigenetic events, which comprise post-translational modifications of histone tails or DNA methylation, control gene expression by altering chromatin structure without change in the DNA sequence. Histone tails modifications are driven by specific cellular enzymes such as histone methyltransferases or histone acetylases, which play a key role in regulating diverse biological processes. Their alteration may have consequences on growth and tumorigenesis. ABSTRACT: Epigenetic regulations, that comprise histone modifications and DNA methylation, are essential to processes as diverse as development and cancer. Among the histone post-translational modifications, lysine methylation represents one of the most important dynamic marks. Here, we focused on methyltransferases of the nuclear binding SET domain 1 (NSD) family, that catalyze the mono- and di-methylation of histone H3 lysine 36. We review the loss of function mutations of NSD1 in humans that are the main cause of SOTOS syndrome, a disease associated with an increased risk of developing cancer. We then report the role of NSD1 in triggering tumor suppressive or promoter functions according to the tissue context and we discuss the role of NSD1 in melanoma. Finally, we examine the ongoing efforts to target NSD1 signaling in cancers. |
format | Online Article Text |
id | pubmed-9563040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95630402022-10-15 Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? Krossa, Imène Strub, Thomas Aplin, Andrew E. Ballotti, Robert Bertolotto, Corine Cancers (Basel) Review SIMPLE SUMMARY: Epigenetic events, which comprise post-translational modifications of histone tails or DNA methylation, control gene expression by altering chromatin structure without change in the DNA sequence. Histone tails modifications are driven by specific cellular enzymes such as histone methyltransferases or histone acetylases, which play a key role in regulating diverse biological processes. Their alteration may have consequences on growth and tumorigenesis. ABSTRACT: Epigenetic regulations, that comprise histone modifications and DNA methylation, are essential to processes as diverse as development and cancer. Among the histone post-translational modifications, lysine methylation represents one of the most important dynamic marks. Here, we focused on methyltransferases of the nuclear binding SET domain 1 (NSD) family, that catalyze the mono- and di-methylation of histone H3 lysine 36. We review the loss of function mutations of NSD1 in humans that are the main cause of SOTOS syndrome, a disease associated with an increased risk of developing cancer. We then report the role of NSD1 in triggering tumor suppressive or promoter functions according to the tissue context and we discuss the role of NSD1 in melanoma. Finally, we examine the ongoing efforts to target NSD1 signaling in cancers. MDPI 2022-10-05 /pmc/articles/PMC9563040/ /pubmed/36230787 http://dx.doi.org/10.3390/cancers14194865 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Krossa, Imène Strub, Thomas Aplin, Andrew E. Ballotti, Robert Bertolotto, Corine Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? |
title | Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? |
title_full | Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? |
title_fullStr | Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? |
title_full_unstemmed | Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? |
title_short | Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma? |
title_sort | lysine methyltransferase nsd1 and cancers: any role in melanoma? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563040/ https://www.ncbi.nlm.nih.gov/pubmed/36230787 http://dx.doi.org/10.3390/cancers14194865 |
work_keys_str_mv | AT krossaimene lysinemethyltransferasensd1andcancersanyroleinmelanoma AT strubthomas lysinemethyltransferasensd1andcancersanyroleinmelanoma AT aplinandrewe lysinemethyltransferasensd1andcancersanyroleinmelanoma AT ballottirobert lysinemethyltransferasensd1andcancersanyroleinmelanoma AT bertolottocorine lysinemethyltransferasensd1andcancersanyroleinmelanoma |